19.02.2013 - The European Commission has announced it will launch an observatory to map progress and impact of the development of the EU's bioeconomy.
The observatory, which is part of the EC's bioeconomy action plan, will gather data to follow the evolution of markets, to map EU, national and regional bioeconomy policies, research and innovation capacities, and the scale of related public and private investments. The Commission's in-house science service JRC will run the new resource.
"It's now one year since we launched our bioeconomy strategy“, said Research Commissioner Máire Geoghegan-Quinn in Brussels. „We are now seeing Member States seize the opportunity offered by the transition to a post-petroleum economy based on smart use of resources from land and sea. It's essential that they do because it will be good for our environment, our food and energy security, and for Europe's competitiveness in the future. This observatory will help keep the momentum going."
The observatory will start its 3-year term in March 2013 with the aim of making the data it will collect publicly available through a dedicated web portal in 2014. In this way, the observatory will support the regional and national bioeconomy strategies now being developed by EU Member States. The observatory will track a number of performance measures, including economic and employment indicators, innovation indicators, and measures of productivity, social wellbeing and environmental quality. It will also provide a "technology watch” and “policy watch” and will follow the development of science and technology.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.